Predicting Lung Deposition of extrafine ICS Containing Fixed Combinations COPD patients using FRI in an in silico study.

In a recent study by Usmani et al. , FRI was used to evaluate lung deposition of extrafine beclomethasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB) and extrafine BDP/FF delivered through pressurized metered dose inhalers and to compare results with reference gamma scintigraphy data. FRI combined high-resolution computed tomography scans of 20 patients with moderate-to-severe chronic obstructive pulmonary disease with in silico computational flow simulations, and incorporated drug delivery parameters to calculate aerosol airway deposition. Inhalation was simulated using profiles obtained from real-life measurements.

FRI demonstrated similar deposition patterns for both formulations, both having a high lung deposition. Moreover, the deposition patterns of BDP and FF were similar. Furthermore, the C:P ratios of both products indicated a high peripheral deposition, supporting small airway targeting and delivery of these two extrafine fixed combinations, with a small difference in ratios potentially due to mass median aerodynamic diameters.

The results reported in this study further support FRI as a validated method to assess lung aerosol deposition, without the setup of a clinical trial and the modification of the drug for radiolabeling as required in scintigraphy.

Categorised in: Miscellaneous / February 23, 2021 10:55 am / Published by Fluidda